Vivos Therapeutics (VVOS) EBITDA Margin (2020 - 2026)
Vivos Therapeutics (VVOS) reported EBITDA Margin of 122.84% for Q1 2026, up 44.0% year-over-year from 85.3% in Q1 2025, and up 28.63% quarter-over-quarter from 172.12% in Q4 2025.
Vivos Therapeutics (VVOS) EBITDA Margin (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has 7 years of EBITDA Margin data on file, last reported at 122.84% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 122.84%, up 44.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 111.39% (down 3752.0% YoY), and the FY2025 annual result was 110.04%, down 3905.0% from the prior year.
- EBITDA Margin improved to 122.84% in Q1 2026 per VVOS's latest filing, from 172.12% in the prior quarter.
- Over five years, EBITDA Margin peaked at 45.29% in Q2 2024 and troughed at 176.7% in Q1 2022.
- A 5-year average of 116.69% and a median of 122.63% in 2022 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2024: EBITDA Margin plunged 34640 bps in 2022, then jumped 8481 bps in 2024.
- A 5-year view of EBITDA Margin shows it stood at 145.9% in 2022, then rose by 17 bps to 121.09% in 2023, then surged by 40 bps to 73.17% in 2024, then slumped by 135 bps to 172.12% in 2025, then grew by 29 bps to 122.84% in 2026.
- Business Quant data shows VVOS's EBITDA Margin at 122.84% in Q1 2026, 172.12% in Q4 2025, and 63.9% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 16.24% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 28.97% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 14.52% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 21.42% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 10.04% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 19.94% |
| 10 | Vivos Therapeutics | 7.39 Mn | 5.16 Mn | 3.06 Mn | -122.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -122.84% |
| Dec 31, 2025 | -172.12% |
| Sep 30, 2025 | -63.90% |
| Jun 30, 2025 | -119.50% |
| Mar 31, 2025 | -123.28% |
| Dec 31, 2024 | -73.17% |
| Sep 30, 2024 | -65.93% |
| Jun 30, 2024 | -45.29% |
| Mar 31, 2024 | -107.78% |
| Dec 31, 2023 | -121.09% |
| Sep 30, 2023 | -107.24% |
| Jun 30, 2023 | -130.10% |
| Mar 31, 2023 | -124.58% |
| Dec 31, 2022 | -145.90% |
| Sep 30, 2022 | -122.63% |
| Jun 30, 2022 | -161.66% |
| Mar 31, 2022 | -176.70% |
| Dec 31, 2021 | 200.50% |
| Sep 30, 2021 | -118.85% |
| Jun 30, 2021 | -88.51% |